AstraZeneca Nijmegen BV

Primary objectives: 1. To estimate the effectiveness of volrustomig monotherapy by evaluating the confirmed ORR. 2. To evaluate the safety and tolerability of volrustomig monotherapy in study subjects with recurrent/metastatic cervical cancer. Secondary objectives: 1. To estimate the effectiveness of volrustomig monotherapy by DoR evaluation. 2. To estimate the effectiveness of volrustomig monotherapy based on PFS evaluation. 3. To estimate the effectiveness of volrustomig monotherapy based on TTR evaluation. 4. To estimate the effectiveness of volrustomig monotherapy based on OS evaluation. 5. To evaluate the PK of volrustomig. 6. To study the immunogenicity of volrustomig. 7. To estimate the effectiveness of volrustomig in study subjects with positive PD-L1 expression and high PD-L1 expression by investigator-assessed confirmed ORR.

Primary objective: To evaluate the effect of AZD3427 on PVR in subjects with HF and PH (category 2) after 24 weeks of treatment. Secondary objectives: To evaluate the effect of AZD3427 on other hemodynamic markers of cardiac function in subjects with HF and PH (category 2) after 24 weeks of treatment; To evaluate the effect of AZD3427 on function and symptoms in subjects with HF and PH (category 2) after 24 weeks of treatment; To evaluate the effect of AZD3427 on cardiac and renal function biomarkers in subjects with HF and PH (category 2) after 12 and 24 weeks of treatment; To evaluate the PK of AZD3427 after repeated Q2W SC administration in subjects with HF and PH (category 2); To evaluate the immunogenicity of AZD3427. Safety objective: To evaluate the safety and tolerability of AZD3427 compared with placebo in subjects with HF and PH (category 2).

Evaluating the efficacy and safety of inelizumab in Chinese adult patients with NMOSD